AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP) October 13, 2020 - NASDAQ Companies 0 Bay Street News » View More News for October 13, 2020
